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Abstract
Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours
in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy,
this is associated with long-term toxicities and chemo-resistance. Roles for receptor tyrosine kinases other
than KIT are largely unknown in TGCT. We therefore conducted a phosphoproteomic screen and identified the
insulin growth factor receptor-1 (IGF1R) as both highly expressed and activated in TGCT cell lines representing
the nonseminomatous subtype. IGF1R was also frequently expressed in tumour samples from patients with
nonseminomas. Functional analysis of cell line models showed that long-term shRNA-mediated IGF1R silencing
leads to apoptosis and complete ablation of nonseminoma cells with active IGF1R signalling. Cell lines with high
levels of IGF1R activity also showed reduced AKT signalling in response to decreased IGF1R expression as well
as sensitivity to the small-molecule IGF1R inhibitor NVP-AEW541. These results were in contrast to those in the
seminoma cell line TCAM2 that lacked IGF1R signalling via AKT and was one of the two cell lines least sensitive to
the IGF1R inhibitor. The dependence on IGF1R activity in the majority of nonseminomas parallels the known role
of IGF signalling in the proliferation, migration, and survival of primordial germ cells, the putative cell of origin for
TGCT. Upregulation of IGF1R expression and signalling was also found to contribute to acquired cisplatin resistance
in an in vitro nonseminoma model, providing a rationale for targeting IGF1R in cisplatin-resistant disease.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Testicular germ cell tumours (TGCTs) are themost com-
mon solid malignancy in young adults and adolescents.
They comprise twomajor histological subtypes: semino-
mas, which resemble primordial germ cells (PGCs), the
likely precursors of TGCT; and nonseminomas, which
display features of embryonic, extra-embryonic, and
somatic tissue. TGCTs are thought to originate through
improper development of PGCs and/or gonocytes
(reviewed in ref 1). Signalling through the KIT receptor
tyrosine kinases (RTKs) is important in this process,
as this, and more recently IGF1R, has been shown to
promote the motility and survival of PGCs [2–4].
Over 95% of patients presenting with TGCT are
cured, either through orchidectomy at an early stage
or by the effective use of combination cisplatin-based
chemotherapy [5]. Patients who present with poor
risk features (extremely high tumour markers,
non-pulmonary visceral metastases or mediastinal
primary tumour) have survival rates below 70% and
despite initial favourable responses, cisplatin resistance
can develop [6]. The typically young age at diagnosis
means that, on average, approximately 36 years of
life are lost per man dying of TGCT from an average
81.5 years’ life expectancy in the UK [6]. Overcoming
chemo-resistance is key to improving survival in poor
prognosis patients.
Inhibition of RTKs has realized their therapeutic
potential in a range of cancers over the past decade.
Humanized monoclonal antibodies such as trastuzumab
(ERBB2 inhibitor) and bevacizumab (VEGF inhibitor)
successfully target either the RTK or its ligand to block
downstream signalling. Small-molecule inhibitors of
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
IGF1R signalling in TGCT 243
intracellular RTK signalling also have proven activity
in many tumour types [e.g. imatinib and gastrointestinal
stromal tumour (GIST), sunitinib and renal cell carci-
noma, and erlotinib in non-small cell lung cancer [7–9]].
Previous work by us and others has shown the involve-
ment of RTK signalling in seminomas (SEs) by showing
that the gene encoding KIT is amplified (21% of SEs)
[10,11], expressed (78–100% of SEs) [12–15], and
mutated (10–25% of SEs), together suggesting a strong
selection pressure for KIT signalling in SE [16–18]. A
reduction in viability in response to siRNA-mediated
silencing of KIT in SE cells suggests dependency in this
cell type [19].
There is growing evidence that indicates a role for
activation of the RAS, MAP kinase, and PI3-kinase
pathways in both the seminoma and the nonseminoma-
tous subtypes of TGCT [20–22]. Downstream elements
of RTK signalling activated in TGCT include genomic
gain of RASGEF1A and loss of inhibitory factors such
as PTEN [20] and PIK3IP1 [22]. Gain of 12p is a hall-
mark of TGCT and the minimum region of amplification
almost invariably includes the KRAS gene [10,23].
Upregulation of RAS signalling occurs through activat-
ing mutations of RAS genes (KRAS, NRAS, and HRAS)
with a combined frequency of 8% [24,25]. Activating
BRAF mutations are reported in 9% of nonseminomas
and have been linked with a poorer prognosis [25,26].
However, ERK is constitutively active in TGCT, irre-
spective of the mutation status of upstream signalling
components KIT , RAS or BRAF [16,25]. The PI3-kinase
pathway is activated via loss of heterozygosity (36%),
inactivating mutations (9%), and decreased expression
of the PI3-kinase inhibitor PTEN (72%) in TGCT [20].
Additionally, genome-wide association studies have
implicated polymorphisms in downstream effectors of
RTKs in predisposition to TGCT [1,27]. Together, there
is strong evidence for upregulation of pathways known
to signal downstream of RTKs in both the seminoma
and the nonseminoma subtypes of TGCT. However, evi-
dence for which RTKs contribute to TGCT behaviour,
beyond KIT in seminomas, is limited.
The aim of this study was to identify a role for specific
RTK activity in TGCT. We first screened TGCT cell
lines for RTK phosphorylation and identified IGF1R
as phosphorylated in TGCT. High IGF1R activity was
confirmed in TGCT samples and the dependence on
IGF1R activity was demonstrated in nonseminoma cell
line models, including a model of cisplatin resistance.
Materials and methods
Cell lines and tissue samples
The human cell lines GCT27, 577MF, TERA1,
NTERA2, 2102 (2102EP), and GCT44 all repre-
sent nonseminomas (TCAM2 resembles seminomas)
and were cultured as described previously [28–33].
SuSa (cisS), a human teratoma-derived cell line, and
its cisplatin-resistant subline SuSa cisR have been
described previously [34,35]. Samples were collected
from TGCT patients (summarized in the supplementary
material, Table S1) at the Royal Marsden Hospital NHS
Foundation Trust. Informed consent was obtained from
all patients; the study was approved by the Institute of
Cancer Research/Royal Marsden Hospital Committee
for Clinical Research (study number CCR2014) and
procedures were in accordance with the Helsinki Dec-
laration. Total RNA was extracted from frozen TGCT
samples as described previously [24]. Normal tissue
RNAs (smooth muscle, lung, uterus, skin, ovary, adi-
pose, brain, stomach, bladder, thymus, placenta, thyroid,
small intestine, spleen, pancreas, colon, bone marrow)
were obtained from BD Biosciences (Palo Alto, CA,
USA). TGCT formalin-fixed, paraffin-embedded tissues
[see below for immunohistochemistry (IHC) and asso-
ciated tissue microarrays (TMAs)] have been described
previously [36].
Phospho RTK screen
The Human Phospho-RTK Array Kit (ARY001) (R&D
Systems, Abingdon, UK) was used according to the
manufacturer’s recommendations. This antibody-based
technique simultaneously determines the levels of phos-
photyrosine in 42 RTKs per sample. 5 × 106 cells grown
in normal serum were harvested and pelleted, and then
resuspended in 500 μl of NP-40 lysis buffer and pre-
cleared. Lysates were quantified using the Bio-Rad DC
Protein Assay (Bio-Rad, Hemel Hempstead, UK).
Five hundred micrograms of cell line protein
was added to each array and incubated for 16 h at
2–8 ∘C before washing according to the manufac-
turer’s instructions. 1.5ml of freshly diluted (1:2000)
Anti-Phospho-Tyrosine-HRP Detection Antibody was
added to each well and incubated for 2 h at room tem-
perature. Arrays were developed using ECL Plus (GE
Healthcare, Amersham, UK) according to the manufac-
turer’s instructions and activity was detected using the
Molecular Imager ChemiDoc XRS System (Bio-Rad).
The signal intensity was independently assessed on a
grading system of 0–5 by three individuals and the
consensus score was used (as described previously
[37]). Each blot was also analysed by densitometry
and each RTK intensity was expressed as a fraction of
the total signal on the membrane. The ranking of RTK
signal intensity by each method was highly similar.
Phospho-IGF1R ELISA
Cells were either unstimulated or stimulated with IGF-1
(Peprotech EC Ltd, London, UK) or IGF-2 (Peprotech
EC Ltd) at 50 ng/ml in normal serum for 5min prior to
lysis. Cell lysates were quantified using the BCAProtein
assay (Thermo Fisher Scientific, Waltham, MA, USA).
The phospho-IGF1R ELISA assay (R&D Systems) was
used according to the manufacturer’s instructions using
100 μg of protein per well. Absorbance at 450 nm was
measured on an ELx800 Absorbance Microplate Reader
(BioTek, Swindon, UK).
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Immunoblotting
Protein was extracted from cell lines using lysis
buffer [Cell Signaling Technology (CST), Leiden, The
Netherlands]. Lysates were transferred onto polyvinyli-
dene difluoride membrane using the iBlot system
(Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Antibodies {IGF1R (3027; CST),
phospho-AKT (9271, Ser473; CST), AKT (9272;
CST), phospho-IGF1R (Tyr1316) (6113; CST), phos-
photyrosine (4G10; Merck Millipore, Watford, UK),
phospho-ERK (Thr202/Tyr204) (9107; CST), ERK
(9102; CST), phospho-STAT3 (Tyr705) (9145; CST),
STAT3 (9139; CST), TUBA1A (α-tubulin) [sc-8035;
Santa Cruz Biotechnology (SCBT), Dallas, TX, USA],
ACTB (sc-47778; SCBT) and GAPDH (MAB374; 1:10
000; Merck Millipore)} were diluted 1:1000 unless
otherwise stated in 1% milk–TBST and blots were
incubated overnight at 4 ∘C with agitation. Antibody
staining was detected with ECL Prime reagent (GE
Healthcare), according to the manufacturer’s instruc-
tions. Band intensities were digitally measured using
ImageJ software [38,39].
Immunoprecipitation
Five hundred micrograms of whole cell lysate was
adjusted to 1 μg/μl in cell lysis buffer and supple-
mented with activated sodium vanadate (final concen-
tration 40mM). IGF1R antibody (1:50 dilution; CST) or
normal rabbit IgG (1 μg; SCBT) was added to diluted
lysates and rotated overnight at 4 ∘C. Dynabeads Pro-
tein A (50 μl; Thermo Fisher Scientific) were added to
lysates and rotated at 4 ∘C for 3 h. The supernatants
were then removed and the beads washed according
to the manufacturer’s instructions. Immunoprecipitated
proteins were eluted by placing beads at 70 ∘C in 20 μl
of 1× LDS Sample Buffer, 50 μM dithiothreitol (DTT;
Thermo Fisher Scientific). The eluates were then sub-
jected to immunoblotting.
Immunohistochemistry
Previously described TMAs [36] were deparaffinized
and immunostained with a primary antibody for IGF1R
(#3027; CST). Staining was performed on the Leica
Bond III platform using Bond Polymer Refine DAB
detection (Leica Biosystems, Newcastle-upon-Tyne,
UK). Antibody was applied at a dilution of 1/200
for 15min at room temperature, following on-board
heat-mediated epitope retrieval using Leica Epitope
Retrieval 2 solution (pH 9) for 30min at 99 ∘C (per-
formed by University College London Advanced
Diagnostics). Colon tissue sections were used as con-
trols where discrete specific membranous staining of
glandular cells was observed as expected. Slides were
analysed by pathologists (SP and KT) and samples
with at least two scorable cores were scored posi-
tive if more than 10% of cells showed membranous
staining.
RT-qPCR
cDNA was produced from RNA using Superscript
II reverse transcriptase (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions.
Real-time RT-PCR was performed using the ABI
PRISM 7900 Sequence Detection System according
to the manufacturer’s instructions (Thermo Fisher
Scientific). Pre-designed primer and probe sets for
test (IGF1R Hs99999020_m1) and control (B-Actin
4310881E-0803023) genes were used (Thermo Fisher
Scientific). Expression was averaged across triplicate
repeats, quantified against a standard curve.
Copy number analysis
Copy number analysis was carried out using nor-
mal male genomic DNA as a calibrator (Promega,
Southampton, UK) by real-time PCR on the Viia7
instrument (Thermo Fisher Scientific) according to the
manufacturer’s instructions, using IGF1R copy number
assay (Hs05381099_cn) and internal reference control
gene (RPPH1) assay (Thermo Fisher Scientific). All
reactions were performed in triplicate.
siRNA knockdown of target genes
Transfections were carried out according to the manu-
facturer’s instructions, using Lipofectamine 2000 (Invit-
rogen, Carlsbad, CA, USA), siRNA duplexes that tar-
geted IGF1R (Hs_IGF1R_1HP,Hs_IGF1R_7HP) (Qia-
gen, Hilden, Germany), and a non-targeting control
siRNA (Dharmacon, Lafayette, CO, USA) at 33 nM.
Each transfection included six replicates.
Lentiviral transfection
shRNA sequences targeting IGF1R (MISSION®
TRC shRNA TRCN0000000424; Sigma-Aldrich,
Poole, UK) and a non-targeting control (SHC002;
Sigma-Aldrich) were used in lentiviral shRNA knock-
down. Lentivirus production and transduction were as
previously described [40]. Two days post-transduction,
cells were selected in either 2 μg/ml (NTERA2, GCT44,
SuSa) or 5 μg/ml (TCAM2) puromycin.
Proliferation
Cellular proliferation was assessed using a CyQUANT
NF Cell Proliferation Assay Kit (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. Fluo-
rescence intensity was measured (excitation at 485 nm,
emission at 535 nm) using a VICTOR2 D fluorometer
(PerkinElmer, Beaconsfield, UK). Cells were counted
directly using a haemocytometer following lentiviral
experiments.
GI50 assays
Cells were plated at 4000 cells per well in a 96-well
plate. The following day, media were replaced with
media containing NVP-AEW541 (Selleck Chemicals;
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Table 1. RTK phosphorylation in TGCT cell lines using phospho arrays
Cell line
Antibody GCT27 GCT44 2102 577MF TERA1 TCAM2 NTERA2
IGF1R 2 3 2 5 3 4 4
INSR 2 3 2 4 3 3 3
TYRO3 3 2 3 3 3 3 3
EPHB2 2 2 2 2 2 2 2
EGFR 2 1 1 2 N 2 3
PDGFRB 0 2 2 1 3 1 3
ROR1 2 1 2 1 2 2 2
MSPR 1 1 2 2 2 1 2
ROR2 1 1 1 2 3 1 1
MERTK 1 1 1 2 N 1 2
TEK 1 1 1 2 N 1 2
FGFR2 0 1 1 2 3 0 1
VEGFR2 0 1 1 2 3 0 1
ERBB4 1 1 1 1 2 0 1
FGFR3 0 1 1 1 1 1 2
RET 1 1 1 1 2 0 1
NTRK2 1 1 1 1 2 0 1
EPHA1 1 1 1 1 2 0 1
ERBB3 1 2 0 1 2 0 0
TIE1 1 1 1 1 1 0 1
VEGFR3 0 1 1 1 1 0 2
EPHA2 1 1 0 2 1 0 1
EPHA4 1 1 0 3 1 0 0
EPHA7 0 0 1 1 N 0 3
PDGFRA 0 1 1 1 1 0 1
FLT3 0 1 1 1 1 0 1
CSF1R 0 1 1 1 1 0 1
EPHB6 0 0 1 1 1 1 1
ERBB2 1 1 0 1 N 0 1
NTRK1 0 1 1 1 N 0 1
AXL 0 0 0 1 0 0 3
VEGFR1 0 1 1 1 0 0 1
EPHB1 0 1 0 1 1 0 1
EPHB4 0 0 1 1 1 0 1
FGFR1 0 0 1 1 1 0 0
NTRK3 0 0 0 1 1 0 1
MUSK 0 0 0 1 1 0 1
FGFR4 0 0 0 1 1 0 0
KIT 0 1 0 0 0 0 1
EPHA3 1 0 0 1 0 0 0
MET 0 0 0 0 N 0 0
EPHA6 0 0 0 0 N 0 0
The phosphorylation of each RTK spotted onto the phospho array represented by signal density was assessed on a scale of 0–5, 0 being no detectable signal and 5
being a very strong signal. The average score across all cell lines was used to determine the overall ranking of RTK phosphorylation. N indicates that the signal was
unable to be assessed for this cell line, due to high local background.
Stratech Scientific, Newmarket, UK) using DMSO
as a carrier control (0.1%). Cells were incubated
for 72 h before being assayed for viability using the
CellTiter Aqueous One Solution Cell Proliferation
Assay (Promega) following the manufacturer’s instruc-
tions. Absorbance at 490 nm was measured on an
ELx800 Absorbance Microplate Reader (BioTek).
Caspase-Glo 3/7 apoptosis assay
Quantitation of caspase 3/7 activity using the
Caspase-Glo 3/7 Assay (Promega) was performed
according to the manufacturer’s instructions. Paral-
lel cultures were counted using a haemocytometer
to account for discrepancies in cell number between
samples. The signal was quantified using an MLX
luminometer (Dynex Technologies, Worthing, UK).
Results
Phosphorylation RTK screen identifies IGF1R
as activated in TGCT
Seven TGCT cell lines, including six nonsemino-
mas and one seminoma, were profiled using antibody
arrays to determine the major RTKs activated (sup-
plementary material, Figure S1). The average over all
cell lines was used to rank the activity of the RTKs
(Table 1). IGF1R was the RTK with the most activ-
ity, five out of seven lines showing high levels of
phosphorylation. The insulin receptor, which can het-
erodimerize with IGF1R, also demonstrated high levels
of phosphorylation in a similar pattern to IGF1R, con-
sistent with the concept that the IGF pathway is active
in TGCT.
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Figure 1. Phospho-IGF1R levels in TGCT cell lines in response to
IGF-1 and IGF-2 ligand. (A) Phospho-IGF1R levels were inde-
pendently assessed by ELISA in cells (in normal serum) unstim-
ulated or stimulated with 50 ng/ml IGF-1 or IGF-2 for 5min.
(B) Immunoprecipitation and consequent immunoblotting with
anti-phosphotyrosine were also carried out with unstimulated or
IGF-1-stimulated cells. (C) Activated levels of IGF1R/INSR and AKT
were also assessed in all cell lines by immunoblotting. Densitometry
data corresponding to these blots are shown in the supplementary
material, Figure S3.
Validation of IGF1R phosphorylation in TGCT cell
lines
Two approaches were used to substantiate high IGF1R
activity. Phosphorylation of IGF1R in TGCT cell
lines was initially confirmed using a phospho-IGF1R
ELISA assay including response to IGF1R ligands
IGF-1 and IGF-2 (Figure 1A), followed by immuno-
precipitation (IP) of IGF1R and immunoblotting with
anti-phosphotyrosine antibodies (Figure 1B). The
ELISA and immunoprecipitation assays indicated that
unstimulated phospho-IGF1R levels were generally
low, with the only seminoma cell line, TCAM2, having
detectable levels by IP. However, four of the six non-
seminoma cell lines (GCT44, NTERA2, TERA1, and
577MF) showed a robust response to IGF-1 and IGF-2
stimulation by ELISA and IP. Upon IGF-1 stimulation,
TCAM2 showed moderate pIGF1R levels by ELISA
but no increase by IP. GCT27 and 2102, which had
the lowest pIGF1R levels on the RTK arrays, showed
little or no increase in activity when stimulated by IGFs
using either method.
IGF1R activity induces AKT signalling
The levels of pAKT induction when the IGF1R pathway
is activated were also investigated (Figure 1C). GCT44,
NTERA2, and 577MF showed high levels of pAKT in
response to IGF-1 stimulation, whereas TERA1 showed
a more modest induction. pAKT was undetectable in
2102 cells and did not increase with IGF-1 stimulation in
TCAM2 cells. Although GCT27 cells had low amounts
of pIGF1R, an increase in pAKT levels was observed
with IGF-1 stimulation. Together, these results support
IGF pathway activity and response to ligand in four out
of six nonseminoma cell lines, which was not seen in the
seminoma cell line.
IGF1R is highly expressed in normal testes
and clinical TGCT samples
The expression level of IGF1R was analysed in tumour
samples by RT-qPCR. Expression of IGF1R was sig-
nificantly higher in both nonseminomas and semino-
mas than in normal tissues (p= 0.005 and p= 0.013,
respectively; two-tailed t-test with Welch’s correction)
(Figure 2A). However, the difference between nonsemi-
nomas and seminomas did not reach statistical signifi-
cance (p= 0.0768). The median expression of IGF1R in
normal tissues was considerably lower than in normal
testis (0.28-fold, data not shown), indicating that IGF1R
expression is relatively high in normal testis. All but
one nonseminoma sample demonstrated higher IGF1R
expression than the median of the normal tissue panel.
IGF1R expression in TGCT was also investigated
by immunohistochemistry on tissue microarrays repre-
senting 178 cases. Overall, 73/148 (49%) nonsemino-
mas expressed IGF1R (Figure 2B) and the majority of
seminomas and germ cell neoplasia in situ cases were
positive (Table 2, Figure 2B, and supplementary mate-
rial, Table S2). A chi-squared test for trend analysis to
detect a difference between staining in nonseminomas
and seminomas approached significance (p= 0.0531).
IGF1R knockdown reduces growth and causes
apoptosis in nonseminoma cells
The functional consequences of silencing IGF1R
expression were assessed in cell lines. NTERA2 and
GCT44 were chosen as model nonseminoma cell lines
as they both have high activation of IGF1R. siRNA
knockdown with two different siRNAs resulted in a
strong reduction in viability in both NTERA2 (45%
reduction at 96 h post-transfection) and GCT44 (60%
reduction at 96 h post transfection) relative to the
non-targeting siRNA (Figure 3A–C and supplemen-
tary material, Figure S2A) in comparison to a milder
phenotype observed in TCAM2 (25% reduction at 96 h
post-transfection).
Lentiviral IGF1R shRNAs were used to study
the long-term effects of IGF1R knockdown. The
growth of both nonseminoma cell lines was severely
affected after shRNA-mediated reduction of IGF1R.
By day 17 post-transduction, IGF1R-silenced cells of
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Figure 2. IGF1R expression at protein and mRNA level in primary
TGCT samples. (A) IGF1R mRNA levels in the two histological sub-
types of TGCT, cell lines, and normal testis as compared to the
median level in a panel of normal tissues (set to 1 and indicated by
a dashed line) as assessed by RT-qPCR. (B) Representative images
of IGF1R expression in nonseminomas as assessed by IHC. Negative
expression (top left), weak expression (top right), moderate expres-
sion (bottom left), and strong expression (germ cell neoplasia in situ
case, bottom right). Scale bar indicates 50 μm.
NTERA2 and GCT44 were dead in comparison to the
actively growing cells transduced with a control shRNA
(Figure 3D, E and supplementary material, Figure
S2B). On day 8 post-transduction, the cells with IGF1R
knockdown were undergoing apoptosis, as shown by a
significant increase in the caspase 3/7 activity (p< 0.05)
in NTERA2 cells (supplementary material, Figure
S2C). In contrast, TCAM2, GCT27, and 2102 cells
continued to actively divide with IGF1R silencing,
albeit at a retarded rate compared with the control
shRNA-containing cells, with GCT27 cells demon-
strating the largest proliferative difference and 2102
cells the smallest (Figure 3F–H). This is consistent
with the proliferative phenotype observed after siRNA
knockdown of IGF1R, where IGF1R knockdown had a
greater impact on the number of viable NTERA2 and
GCT44 cells relative to the non-targeting control and
TCAM2 had the mildest phenotype.
IGF1R silencing leads to attenuated phospho-AKT
signalling in nonseminoma cells and correlates
with sensitivity to the IGF1R inhibitor NVP-AEW541
In order to assess the therapeutic potential of tar-
geting IGF1R in TGCT, NVP-AEW541, an IGF1R
inhibitor, was used in GI50 assays (Figure 4A). The
IGF1R inhibitor was effective at inhibiting IGF1R and
AKT phosphorylation in response to IGF-1 stimulation
at all concentrations in all cell lines (Figure 4B–D). The
most sensitive cell lines were those that had shown high
levels of IGF1R phosphorylation in response to IGF
stimulus. The seminoma cell line TCAM2was one of the
most resistant lines to NVP-AEW541 inhibition, consis-
tent with a mild phenotypic response to IGF1R silenc-
ing, and the 2102 cell line, which demonstrated the low-
est phospho-AKT levels, was the most resistant.
Sensitivity to NVP-AEW541 in our cell line panel
broadly reflects IGF1R activity, although the GCT27
cell line was moderately sensitive despite having very
low levels of phospho-IGF1R. The low activity of
IGF1R in GCT27 may significantly alter downstream
signalling. To investigate this possibility, we assessed
the effects of silencing IGF1R on signalling pathways
downstream of IGF1R in response to IGF-I stimula-
tion (Figure 5). In cell lines that appear to depend on
IGF1R signalling, such as GCT44, and have the highest
sensitivity to an IGF1R inhibitor, such as TERA1,
siRNA-mediated downregulation of IGF1R led to
decreased phospho-AKT when stimulated with IGF-I
(Figure 5A, B). This was also the case for the GCT27
line (Figure 5C), whereas phospho-AKT levels did not
alter when IGF1R was silenced in TCAM2 cells, which
do not have a high dependence on IGF1R signalling and
are more resistant to the inhibitor (Figure 5D). Changes




No of tumours with
IGF1R expression
Percentage of tumours
with IGF1R expression (%)
TMA 1 GCNIS 14 11 79
Seminoma 16 13 81
Nonseminoma 82 34 41
TMA 2 Stage 1 nonseminoma 66 39 59
Total Nonseminoma 148 73 49
Total All subtypes 178 97 54
GCNIS: germ cell neoplasia in situ.
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Figure 3. Silencing of IGF1R reduces growth in nonseminoma cell lines. Nonseminoma cell lines GCT44 (A) and NTERA2 (B) exhibited
reduced growth upon IGF1R knockdown by two independent siRNAs, whereas the seminoma cell line TCAM2 showed only modest growth
retardation (C). Following lentiviral transduction of IGF1R shRNA and selection, the nonseminoma cell lines GCT44 (D) and NTERA2 (E) were
eliminated by day 18 of culture in contrast to the seminoma cell line TCAM2 (F) and 2102 (H), which demonstrated a small reduction in
cell number after 17 days in culture; GCT27 (G) showed an intermediate response.
in the levels of phospho-ERK and phospho-STAT3 upon
IGF1R silencing were not observed.
IGF1R protein expression is increased in the
acquired cisplatin-resistant TGCT model cell line
and IGF1R silencing leads to cisplatin
resensitization
IGF1R has previously been implicated in cisplatin resis-
tance in ovarian cancer [41]. We therefore investi-
gated the SuSa cell line model of cisplatin resistance
[35] to determine if IGF1R signalling was enhanced
in SuSa cisplatin-resistant (SuSa cisR) cells compared
with the parental cisplatin-sensitive cells (SuSa cisS).
IGF1R protein was upregulated in the resistant cells
that increased phospho-AKT signalling when stimulated
with IGF-1, and had the highest expression of IGF1R
of all the cell lines in this study (Figure 6A, B). The
resistant subline also had increased basal phospho-AKT
levels compared with the sensitive line (Figure 6B).
IGF1R expression and copy number were increased
1.5-fold in the resistant cells compared with the sen-
sitive line (Figure 6C, D). We transduced SuSa cisR
cells with either IGF1R shRNA or control non-silencing
(NS) lentivirus and following selection in puromycin
and replating, we exposed cells to various doses of cis-
platin. The GI50 for cisplatin was reduced in the IGF1R
shRNA transduced cells compared with the NS-treated
cells (Figure 6E). This difference in sensitivity was seen,
although there was no clear difference in cell viabil-
ity (Figure 6F). However, despite effective knockdown
(Figure 6G), residual expression remained quite high
and could explain this. Overall, this provides evidence
for IGF1R activity contributing to cisplatin resistance
in TGCT.
Discussion
Here, we have identified active IGF1R signalling and
have demonstrated that this plays a key role in maintain-
ing nonseminoma cell viability and can also contribute
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Figure 4. Sensitivity of TGCT cell lines to the IGF1R inhibitor
NVP-AEW541. (A) The GI50 of TGCT cell lines to NVP-AEW541 was
measured following 72 h exposure of varying concentrations of
inhibitor (in normal serum). (B–D) Cells were grown in 1% serum
overnight (16 h) and then treated with various concentrations of
NVP-AEW541 (indicated in μM) for 3 h, after which cells were stim-
ulated with IGF-1 (50 ng/ml) for 15min before being lysed and
subjected to immunoblotting.
to cisplatin resistance. Our finding of phosphorylated
IGF1R in nonseminoma cells and high IGF1R expres-
sion levels in patient samples fits with previous observa-
tions noting high serum levels of IGF-2 and IGFBP2 in
nonseminoma patients that reduced after treatment [42].
Similarly, the proportion of cleaved IGFBP3 (which pro-
motes proliferation in breast cancer [43]) is greater in
nonseminoma patients and declines upon response to
treatment.
The RTK KIT and the chemokine receptor CXCR4
are involved in the survival and migration of TGCTs and
also PGCs, the likely precursor cells of TGCT [1,19,36].
IGF1R signalling is also required for the development of
PGCs and gonocytes. Zebrafish models have shown that
the IGF1Rb isoform is required for proper migration and
maintenance of PGC numbers until they reach the geni-
tal ridge [2]. Notably, IGF signalling is also required for
maintaining the germ cell population in postnatal mice
with unilateral undescended testis in both the affected
testis and the contralateral descended testis [44]. Block-
ade of IGF1R signalling or the downstream PI3K path-
way resulted in loss of pluripotency in murine neonatal
spermatogonial stem cells which is maintained by IGF1
produced by the Leydig cells in vivo [45]. Together with
our data, this points to TGCT retaining or recapitulating
the IGF1R signalling observed in the germ cell lineage.
Our data demonstrating that activation of IGF1R sig-
nalling contributes to nonseminoma cell survival are
similar to the functional roles reported for IGF1R in
other cancers, including prostate, breast, and colorec-
tal cancers [46–48]. Although IGF1R kinase activity
can initiate several major signalling cascades including
Figure 5. Attenuation of AKT signalling in nonseminoma TGCT cells
following IGF1R siRNA treatment. Following 48 h siRNA treatment,
the TGCT cell lines GCT44 (A), TERA1 (B), GCT27 (C), and TCAM2
(D) were grown in 1% serum overnight (16 h) and then stimulated
with 50 ng/ml IGF-1 for 15min before lysis. IGF1R knockdown and
AKT, ERK, and STAT3 activation were assessed by immunoblotting of
whole cell lysates. Densitometry data corresponding to these blots
are shown in the supplementary material, Figure S4.
RAS/RAF/MEK/ERK, PI3K/AKT, and STAT3, we did
not observe perturbation of ERK or STAT3 signalling in
response to silencing IGF1R in TGCT cell lines. Cell
lines demonstrating high phospho-AKT in response to
IGF1 stimulation, which subsequently decreased upon
IGF1R silencing, were the most sensitive to chemical
IGF1R inhibition and silencing. In contrast, the two least
sensitive cell lines either had very low phospho-AKT
levels (in cell line 2102, levels were undetectable) or
did not alter phospho-AKTwhen IGF1Rwas downregu-
lated (TCAM2). In addition, the GCT27 cell line, which
had little active IGF1R, nonetheless exhibited decreased
AKT signalling when IGF1R expression was reduced
and was moderately sensitive to the IGF1R inhibitor,
as well as demonstrating an intermediate proliferative
response to shRNA-mediated silencing. Therefore, AKT
signalling appears to be a key response to IGF1R activa-
tion in TGCT cells. This is consistent with data for rhab-
domyosarcomas, where sensitivity to IGF1R inhibitors
was reversed by constitutively active AKT and, con-
versely, progression of in vivo tumour models was asso-
ciated with AKT reactivation [49].
To date, few studies have evaluated the roles of RTKs
in nonseminomas. A patient with cisplatin-resistant
TGCT responded to trastuzumab, suggesting that
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Figure 6. Upregulation of IGF1R protein and pathway activation in
SuSa cisplatin-resistant (cisR) cells. (A) IGF1R and phospho-AKT are
upregulated in the SuSa cisR subline compared with the parental
sensitive cells (cisS) and show a hyperactive response to IGF-1
stimulation. (B) SuSa cisR cells have the highest IGF1R expression
across all the cell lines used in the study. IGF1R mRNA expression
(C) and copy number (D) are increased in SuSa cisR cells com-
pared with their cisplatin-sensitive counterpart. (E) Reduced IGF1R
expression following shRNA lentiviral transduction results in sen-
sitization of SuSa cisR cells to cisplatin. (F) Cell viability in the
absence of cisplatin treatment was measured as part of the exper-
iment shown in E and normalized to the control shRNA-treated
cells. (G) Immunoblot confirming reduced expression in IGF1R
shRNA-treated cells. Densitometry data corresponding to the blots
in A and B are shown in the supplementary material, Figure S5.
ERBB2 may be an effective target in TGCT [50].
However, subsequent immunohistochemistry shows
that ERBB2 expression is infrequent in TGCT and is
not associated with poorer overall survival [51–54].
ERBB3 has been reported as highly expressed in
TGCT tumours with signal activation dependent on
ERBB2 activation with which it forms heterodimers.
Use of lapatinib, a dual ERBB1 and ERBB2 inhibitor,
reduced tumour growth in an orthotopic animal model,
suggesting that it may be of benefit to a subset of
TGCT patients [55]. EGFR is expressed by 21–89%
of nonseminoma samples [51,52,56,57] and PDGRβ
has been linked to cisplatin resistance [58]. Recently,
ERBB2, EGFR, IGF1R, and other kinases have been
investigated in cell lines [59]. Consistent with these
studies, our phospho-RTK array screen also identified
EGFR and PDGFRβ as the fifth and sixth most active
RTKs in TGCT cell lines, with ERBB receptors ranking
lower. Interestingly, activation of additional RTKs was
identified in our screen including TYRO3 and EPHB2.
Their role in TGCT remains to be elucidated.
Unlike many solid tumours, TGCT cells readily
undergo apoptosis in response to DNA-damaging
agents such as cisplatin via a p53-dependent pathway.
The p53 transcriptional response to DNA damage
appears intact but leads to apoptosis in preference
to cell cycle arrest, due in part to very low levels of
p21 in TGCT cells [60]. In cases of cisplatin resis-
tance, AKT has been shown to be essential for high
cytoplasmic p21 expression, which when reversed by
AKT inhibition restores cisplatin sensitivity [61]. AKT1
mutations have recently been identified exclusively in
cisplatin-resistant germ cell tumours [62], and copy
number gain and concomitant overexpression of AKT1
were a frequent event in a study of intracranial germ cell
tumours, which although clinically and histologically
similar to gonadal germ cell tumours, are more likely to
be refractory to treatment [63]. Phospho-AKT levels are
significantly higher in cisplatin-resistant TGCT cells
compared with sensitive or untreated tumours [58]. This
is consistent with our finding that in one TGCT model
of acquired cisplatin resistance, IGF1R copy number
and mRNA expression were increased in the cells with
cisplatin resistance, accompanied by elevated IGF1R
and phospho-AKT protein levels. Importantly, reducing
IGF1R expression in the resistant subline resensitized
cells to cisplatin, showing that upregulation of IGF1R
can contribute to cisplatin resistance in TGCT.
Single-agent clinical trials employing IGF1R
inhibitors have been largely disappointing, due to a
lack of both wide-scale efficacy and accurate pre-
dictive biomarkers of response. There is conflicting
evidence as to whether expression of IGF1R itself,
as opposed to activated IGF1R, identifies patients as
suitable for IGF1R-targeted therapy [49,64–66]. Our
data identify AKT pathway activation in response to
IGF1R signalling as a key factor. IGF1R inhibition has
resulted in enhanced sensitivity to general cytotoxic
and radiation-based therapies in other cancers [67–69],
and recent results for TGCT cell lines show positive
but mixed results for cisplatin combined with mTOR,
EGFR, and IGF1R inhibitors [59]. Together with our
results, this raises the possibility that combination of
IGF1R inhibition with chemotherapy could promote
resensitization to treatment in chemo-resistant disease.
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